Qvar has been approved by the FDA for the treatment of asthma in children 5-11 years of age. This metered dose inhaler is currently marketed for asthma in adults and children 12 years of age and older.

Qvar utilizes a hydrofluoroalkane (HFA) propellant for the delivery of a novel formulation of beclomethasone dipropionate. Beclomethasone dipropionate is a corticosteroid that produces anti-inflammatory activity. With Qvar, beclomethasone is delivered in smaller-sized particles that allow the medication to reach the small airways of the lung.

According to the American Academy of Allergy, Asthma & Immunology, approximately 18 million Americans have asthma. Asthma is the leading cause of hospitalization and school absenteeism among children under the age of 15.

The following adverse events were reported in clinical trials testing Qvar in individuals 12 years of age and older:

• Headache
• Pharyngitis (sore throat)
• Upper respiratory tract infection
• Rhinitis (nasal inflammation)

In rare instances, hypersensitivity reactions (such as hives, rash and bronchospasm) have been reported following the oral and intranasal inhalation of beclomethasone dipropionate.

Airway inflammation is known to be an important component in the pathogenesis of asthma. Inflammation occurs in both large and small airways. Corticosteroids have multiple anti-inflammatory effects, inhibiting both inflammatory cells and release of inflammatory mediators. It is presumed that these anti-inflammatory actions play an important role in the efficacy of beclomethasone dipropionate in controlling symptoms and improving lung function in asthma. Inhaled beclomethasone dipropionate probably acts topically at the site of deposition in the bronchial tree after inhalation. (from Qvar Prescribing Information)

Qvar was originally developed by the company 3M. In April 2002, Ivax and 3M reported the signing of an agreement that gives Ivax exclusive US rights to the Qvar product.

For additional information on Qvar, please visit www.qvar.com.